EquityBulls

Latest News

Keywords Selected: LifeSciences

IPO News

Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

Zydus partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
Sai Life Sciences Releases Sustainability Report 2024-25
Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India
Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
Eiko LifeSciences Ltd to acquire 51% stake in SSM Formulations Pvt Ltd
Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder
Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
Zydus receives EIR for the injectable facility located at Jarod
Innoxel Lifesciences Successfully Completes EU GMP Inspection by Belgium's FAMHP
Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
Eris Lifesciences to consolidate its stake in Swiss Parenterals
SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger
Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
Zydus' Amplitude receives CE mark for its robotic surgical system 'Andy'
Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg
Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg
Zydus receives tentative approval from USFDA for Budesonide delayedrelease capsules, 4 mg
Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore